The controversial approval of Aduhelm, an Alzheimer’s disease drug from Biogen (NASDAQ: BIIB) pushed shares of the biotech stock through the roof in June. Around one in nine adults age 65 and older are losing their minds to Alzheimer’s disease and Aduhelm is their only treatment option.
Blockbuster Aduhelm sales could push Biogen stock even higher. Before running out to purchase the risky biotech stock, though, there’s another Alzheimer’s drug developer to consider.